6 results about "Apolipoprotein e4" patented technology

This invention relates to a novel truncated mutant apolipoprotein E and its calibrators and quality control methods. The amino acid sequence of the truncated mutant apolipoprotein E is shown in SEQ ID. The diluent for the calibrators and quality control methods for detecting the truncated mutant apolipoprotein E includes a preservative, a protein protection composition, a surfactant composition, an ion stabilizer composition, and a buffer solution. The method for preparing the apolipoprotein E mutant includes the following steps: 1. Determining the specific sequence of the truncated mutant; 2. Determining that the mutation site is located at position 78 of wild-type apolipoprotein E; 3. Containing the NdeI site and the mutation sequence; locking the mutation; artificially optimizing the apolipoprotein E nucleotides using E. coli; 4. Extracting the corresponding truncated mutant by electrophoresis; 5. Obtaining the truncated mutant apolipoprotein E through recombination with E. coli. This invention solves the problems of discrepancies between detection results and actual clinical applications, as well as the poor stability of apolipoprotein E calibrators.

This invention discloses an antibody for detecting apolipoprotein E4 and its application, specifically involving a detection antibody and kit for detecting ApoE4, a blood marker of Alzheimer's disease. Based on this antibody and kit, the presence of apolipoprotein E4 can be accurately detected.

The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.

This invention relates to a nucleic acid-lipid nanoparticle for enhanced liver and kidney targeting, its preparation method, and its application. The nucleic acid-lipid nanoparticle comprises lipid nanoparticles and a nucleic acid drug encapsulated therein. The raw materials for preparing the lipid nanoparticles include myristoylphosphatidylcholine, ionizable lipids, cholesterol, and triglycerides. The nucleic acid drug is an siRNA drug. Based on the crucial role of apolipoprotein E in liver-specific recognition and endocytosis, this invention enhances and predictably regulates liver delivery efficiency by modulating the interaction between the molecular structure of helper phospholipids in the lipid nanoparticles and apolipoprotein E, providing a general and scalable design strategy for liver-targeted delivery of nucleic acid drugs.

This invention discloses an immunochromatographic assay kit, preparation method, and application for the detection of apolipoprotein E4. The kit includes a test card and sample diluent. The test card comprises a test strip, which includes a PVC base, absorbent paper, a glass fiber pad, and a nitrocellulose membrane. The glass fiber pad is loaded with polystyrene latex microspheres for physical adsorption. The surface of the polystyrene latex microspheres is modified with sulfonyl or hydroxyl groups, and the zeta potential ranges from -15V to -20V. After the polystyrene latex microspheres are uniformly coated on a glass slide and dried, the contact angle between them and water droplets is greater than 90°. The nitrocellulose membrane is loaded with anti-APOE4 antibody, coating solution, and protein A. The sample diluent includes PBS, TWEEN-20, Tetronic 1307, and CHAPS. This invention eliminates the need for monoclonal antibody-labeled latex microspheres, reducing false positives and reagent batch-to-batch variation, and achieving higher sensitivity.